Back to Search
Start Over
The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
- Source :
-
PloS one [PLoS One] 2019 Aug 13; Vol. 14 (8), pp. e0213130. Date of Electronic Publication: 2019 Aug 13 (Print Publication: 2019). - Publication Year :
- 2019
-
Abstract
- DNA replication stress is a major source of genomic instability and is closely linked to tumor formation and progression. Poly(ADP-ribose)polymerases1/2 (PARP1/2) enzymes are activated in response to replication stress resulting in poly(ADP-ribose) (PAR) synthesis. PARylation plays an important role in the remodelling and repair of impaired replication forks, providing a rationale for targeting highly replicative cancer cells with PARP1/2 inhibitors. The human oncoprotein DEK is a unique, non-histone chromatin architectural protein whose deregulated expression is associated with the development of a wide variety of human cancers. Recently, we showed that DEK is a high-affinity target of PARylation and that it promotes the progression of impaired replication forks. Here, we investigated a potential functional link between PAR and DEK in the context of replication stress. Under conditions of mild replication stress induced either by topoisomerase1 inhibition with camptothecin or nucleotide depletion by hydroxyurea, we found that the effect of acute PARP1/2 inhibition on replication fork progression is dependent on DEK expression. Reducing DEK protein levels also overcomes the restart impairment of stalled forks provoked by blocking PARylation. Non-covalent DEK-PAR interaction via the central PAR-binding domain of DEK is crucial for counteracting PARP1/2 inhibition as shown for the formation of RPA positive foci in hydroxyurea treated cells. Finally, we show by iPOND and super resolved microscopy that DEK is not directly associated with the replisome since it binds to DNA at the stage of chromatin formation. Our report sheds new light on the still enigmatic molecular functions of DEK and suggests that DEK expression levels may influence the sensitivity of cancer cells to PARP1/2 inhibitors.<br />Competing Interests: The authors have declared that no competing interests exist.
- Subjects :
- Bone Neoplasms drug therapy
Bone Neoplasms genetics
Bone Neoplasms metabolism
Chromosomal Proteins, Non-Histone genetics
Genomic Instability
Humans
Oncogene Proteins genetics
Osteosarcoma drug therapy
Osteosarcoma genetics
Osteosarcoma metabolism
Poly-ADP-Ribose Binding Proteins genetics
Tumor Cells, Cultured
Bone Neoplasms pathology
Chromosomal Proteins, Non-Histone metabolism
DNA Damage
DNA Replication
Oncogene Proteins metabolism
Osteosarcoma pathology
Poly (ADP-Ribose) Polymerase-1 antagonists & inhibitors
Poly(ADP-ribose) Polymerase Inhibitors pharmacology
Poly(ADP-ribose) Polymerases chemistry
Poly-ADP-Ribose Binding Proteins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 14
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 31408463
- Full Text :
- https://doi.org/10.1371/journal.pone.0213130